Sugi Predict

Sugi Predict / Targets / NNT

NNT

NAD(P) transhydrogenase, mitochondrial · Q13423 · NNT on Sugi Atlas →

0 patent compounds predicted against NNT, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NNT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis PHASE4NOT_YET_RECRUITING
Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1 PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant PHASE3COMPLETED
Nicotinamide as an Early Alzheimer's Disease Treatment PHASE2COMPLETED
Nicotinamide Riboside in Systolic Heart Failure PHASE1/PHASE2COMPLETED
The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging PHASE2RECRUITING
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD PHASE2ACTIVE_NOT_RECRUITING
Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia PHASE2WITHDRAWN
Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls PHASE2UNKNOWN
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia PHASE1/PHASE2RECRUITING
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients PHASE2RECRUITING
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy PHASE1COMPLETED
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS) PHASE1RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors PHASE1RECRUITING
IV Administration of ChromaDex's Niagen® as Compared to NAD+ nanUNKNOWN
The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults. nanUNKNOWN
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery nanNOT_YET_RECRUITING
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity nanCOMPLETED
Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults nanNOT_YET_RECRUITING
Nicotinamide Riboside Clinical Trial for GWI nanRECRUITING
NOPARK Open Label Extension Study nanACTIVE_NOT_RECRUITING
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+) nanACTIVE_NOT_RECRUITING
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+ nanRECRUITING
Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity nanCOMPLETED
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients nanUNKNOWN
Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement nanRECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment nanCOMPLETED
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults nanCOMPLETED
Nicotinamide and Glaucoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NNT binder may also engage these)

ProteinNameSimilarity
W5PFI3 — 1.000 W5PFI3 →
P11024 — 1.000 P11024 →
Q61941 — 1.000 Q61941 →
P07001 — 0.975 P07001 →
Q9WUM5 — 0.973 Q9WUM5 →
P13086 — 0.971 P13086 →
SUCLG1 Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 0.968 landscape →
Q58DR8 — 0.967 Q58DR8 →
O19069 — 0.966 O19069 →
P28227 — 0.966 P28227 →
Q8BMF3 — 0.966 Q8BMF3 →
Q8GTQ9 — 0.966 Q8GTQ9 →
Q6G543 — 0.966 Q6G543 →
Q8LAD2 — 0.966 Q8LAD2 →
P53596 — 0.966 P53596 →
P68209 — 0.965 P68209 →
A0A0G2KTI4 — 0.964 A0A0G2KTI4 →
Q6ZL94 — 0.964 Q6ZL94 →
Q29554 — 0.964 Q29554 →
Q95028 — 0.964 Q95028 →
B3FHT4 — 0.963 B3FHT4 →
P40927 — 0.963 P40927 →
Q64428 — 0.963 Q64428 →
Q02NB5 — 0.963 Q02NB5 →
A8N0V8 — 0.963 A8N0V8 →
P55014 — 0.963 P55014 →
ME3 NADP-dependent malic enzyme, mitochondrial 0.962 landscape →
Q6DQL1 — 0.962 Q6DQL1 →
C4JZ54 — 0.962 C4JZ54 →
Q949M9 — 0.962 Q949M9 →